Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ EnerSys Announces Dividend of $0.2625 per Share for the First Quarter of Fiscal Year 2027 (Business Wire) +++ ENERSYS Aktie -5,93%

ROCHE HOLDING ADR Aktie

 >ROCHE Aktienkurs 
44.801 EUR    +0.2%    (TradegateBSX)
Ask: 44.801 EUR / 560 Stück
Bid: 44.579 EUR / 560 Stück
Tagesumsatz: 1092 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ROCHE Aktie über LYNX handeln
>ROCHE Performance
1 Woche: +2,1%
1 Monat: +4,0%
3 Monate: -11,3%
6 Monate: +6,3%
1 Jahr: +28,6%
laufendes Jahr: +2,1%
>ROCHE HOLDING ADR Aktie
Name:  ROCHE HOLDING AG ADR
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7711951043 / 891106
Symbol/ Ticker:  RHO6 (Frankfurt)
Kürzel:  FRA:RHO6, ETR:RHO6, RHO6:GR
Index:  -
Webseite:  https://www.roche.com/
Profil:  Roche Holdings Ltd Sponsored ADR represents American Depositary Receipts for Roche Holding AG, a Swiss multinational healthcare company renowned for its leadership in pharmaceuticals and diagnostics. The primary purpose of this financial instrument i..
>Volltext..
Marktkapitalisierung:  281874.4 Mio. EUR
Unternehmenswert:  305563.86 Mio. EUR
Umsatz:  63828.94 Mio. EUR
EBITDA:  23124.57 Mio. EUR
Nettogewinn:  13291.68 Mio. EUR
Gewinn je Aktie:  2.09 EUR
Schulden:  36079.34 Mio. EUR
Liquide Mittel:  6067.76 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  0.55
Umsatzwachstum:  7.88%
Gewinnwachstum:  65.07%
Dividende je Aktie:  1.39 EUR
Dividendenrendite:  1.96%
Dividendenschätzung:  1.9%
Div. Historie:  13.03.26 - 1.3948913€
28.03.25 - 1.1917517€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ROCHE HOLDING ADR, ROCHE, ROCHES
Letzte Datenerhebung:  20.05.26
>ROCHE Kennzahlen
Aktien/ Unternehmen:
Aktien: 5511.41 Mio. St.
Frei handelbar: 100%
Leerverk. Aktien: -
Rückkaufquote: 0.38%
Mitarbeiter: 112774
Umsatz/Mitarb.: 0.57 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 9.78%
Bewertung:
KGV: 21.65
KGV lG: 16.2
KUV: 4.43
KBV: 7.76
PEG-Ratio: 0.33
EV/EBITDA: 13.21
Rentabilität:
Bruttomarge: 73.19%
Gewinnmarge: 20.82%
Operative Marge: 30.72%
Managementeffizenz:
Gesamtkaprendite: 12.89%
Eigenkaprendite: 39.72%
 >ROCHE Anleihen 
>ROCHE Peer Group
 
20.05.26 - 06:42
Aktien von Roche, Novartis und Nestlé am Mittwoch im Anlegerfokus (Cash)
 
Börse - Die drei Index-Schwergewichte im SMI spielen am Mittwoch wohl eine wichtige Rolle....
19.05.26 - 07:36
Roche kündigt neue Daten aus Krebs-Pipeline an (Cash)
 
Pharma - Roche hat für den anstehenden grossen Krebs-Kongress ASCO in den USA neue Studiendaten zu mehreren Krebsmedikamenten angekündigt....
19.05.26 - 07:03
Roche to present new data at ASCO 2026, reinforcing giredestrant′s potential to transform the treatment paradigm in early breast cancer (GlobeNewswire EN)
 
Basel, 19 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held 29 May to 2 June in Chicago....
18.05.26 - 20:39
Roche und MPP unterzeichnen Lizenzvereinbarung für Grippemittel Xofluza (DPA-AFX)
 
ZÜRICH (dpa-AFX) - Roche und die von der UN-unterstützte Gesundheitsorganisation Medicines Patent Pool (MPP) haben eine freiwillige Lizenzvereinbarung für das Grippemedikament Xofluza (Baloxavir Marboxil) unterzeichnet. ......
18.05.26 - 18:15
Roche′s Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer (Zacks)
 
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence....
18.05.26 - 14:03
Roche Highlights Robust Performance of Ellis Bio SuperMethyl™ Kits in New Tech Spotlight Evaluating Five Low‑Input cfDNA Methyl‑Seq Workflows (PR Newswire)
 
Independent Roche evaluation shows SuperMethyl™ Max delivers the highest methylation calling accuracy in the study, producing fewer false calls than both a leading enzymatic methyl-seq (EM‑seq) method and a leading traditional bisulfite kit in low‑input cell-free DNA (cfDNA) workflows.......
18.05.26 - 09:42
AstraZeneca und Roche kooperieren in Asien bei KI-Pathologie (Cash)
 
Pharma - AstraZeneca und Roche Diagnostics haben eine auf drei Jahre angelegte Zusammenarbeit zur Förderung digitaler Pathologie in neun asiatischen Märkten vereinbart....
18.05.26 - 09:42
Roche-Tochter Chugai erhält Zulassungserweiterung für Krebsmittel Alecensa (Cash)
 
Pharma - Die japanische Roche-Tochter Chugai hat für das bereits zugelassene Krebsmittel Alecensa in Japan eine Zulassungserweiterung erhalten....
15.05.26 - 19:57
Roche-Medikament Tecentriq erhält US-Zulassung bei Blasenkrebs (DPA-AFX)
 
WASHINGTON (dpa-AFX) - Die Roche-Krebsimmuntherapie Tecentriq (Atezolizumab) hat in den USA eine Zulassung für die Behandlung einer bestimmten Form von Blasenkrebs erhalten. Es handelt sich um die elfte Indikation für ......
14.05.26 - 18:15
Veeva Systems Expands AI and Vault CRM Momentum: Time to Buy or Hold? (Zacks)
 
VEEV expands Vault CRM adoption and AI capabilities with Roche and BioMarin partnerships as life sciences firms modernize workflows....
12.05.26 - 19:36
Roche-Chef macht Anlegern Mut: Roche kündigt die nächste Wachstumswelle an – drei Medikamente im Fokus (Wallstreet-Online)
 
Roche verspricht Wachstum weit über 2030 hinaus. Neue Medikamente und eine starke Pipeline sollen den Pharmakonzern absichern....
12.05.26 - 17:03
BanyanGlobal Names Stephan Roche Managing Partner (Business Wire)
 
Former Walton Family Enterprises CEO and Cascade executive to lead firm's next chapterBOSTON--(BUSINESS WIRE)--BanyanGlobal Family Business Advisors today announced that partner Stephan Roche has been elected Managing Partner. The appointment comes as Banyan continues to expand its work with complex, multigenerational family enterprises navigating succession, governance, and long-term ownership strategy. Roche is a leading authority on family offices and multigenerational enterprises, with nearly two decades of experience advising globally dispersed families. Before joining Banyan as a partner, he served as CEO of Walton Enterprises, the family office for the Walton family, and as Chief Operating Officer of Cascade Asset Management, the investment office for Bill Gates and the Gates Foundation—two of the most prominent and sophisticated family offices in the world. At Banyan, Roche works at the intersection of ownership, governance, and family dynamics—helping families navigate succession, align acro...
12.05.26 - 13:54
US-Iran Ceasefire Remains Fragile; Starmer Intends to Stay as PM; CPI | Bloomberg Brief 5/12/2026 (Bloomberg)
 
Oil rises and US equity futures fall as President Trump says the ceasefire between the US and Iran is on "life support." UK Prime Minister Keir Starmer tells his Cabinet he will not step down without a fight and intends to stay in power. John Cortese of Apollo Asset Management discusses the credit market with Bloomberg's Francine Lacqua at the JPMorgan Global Markets Conference. Kallum Pickering of Peel Hunt looks ahead to the CPI data. Matt Sause, CEO of Roche Diagnostics, joins as the firm's blood test for Alzheimer's disease wins EU approval. (Source: Bloomberg)...
12.05.26 - 07:31
Roche mit Zulassung für einfachen Bluttest zur Alzheimer-Früherkennung (Cash)
 
Pharma - Roche erhält CE-Kennzeichnung für einen Bluttest, der bei der Diagnose von Alzheimer helfen soll....
12.05.26 - 07:03
Roche receives CE mark for new blood test to detect Alzheimer′s pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (GlobeNewswire EN)
 
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and designed to measure the phosphorylated Tau (pTau) 217 protein, an indicator of amyloid pathology and a hallmark of Alzheimer's disease.1,2,4,7,8 The same cutoffs (high and low) of the blood test can be used across primary and secondary care settings, to rule in or rule out amyloid pathology in people presenting with symptoms or complaints of cognitive decline.1,2,4,5 The early detection of the amyloid pathology is critical for Alzheimer's diagnosis and treatment, as it enables individuals, families, and caregivers to understand the cause of symptoms, access appropriate care, and actively contribute to the planning of next steps.3,4,5,9,10...
10.05.26 - 21:30
Key deals this week: Roche, Bayer, eBay, Bullish, and more (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.26 - 00:48
Live from DoubleLine Capital | The Close 5/7/2026 (Bloomberg)
 
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are DoubleLine Global Sovereign & Emerging Markets Head Bill Campbell, GTCR Co-CEO Collin Roche, DoubleLine Non-Agency Residential Mortgage-Backed Securities Head Ken Shinoda, Cambridge Associates' Samantha Davidson, DoubleLine Deputy CIO Jeffrey Sherman, DoubleLine Global Developed Credit Director Robert Cohen, Man Group CEO Robyn Grew, & DoubleLine CEO & CIO Jeffrey Gundlach. (Source: Bloomberg)...
07.05.26 - 22:18
PE Risk Is Being Priced in a More Rational Way, GTCR′s Roche Says (Bloomberg)
 
GTCR Co-CEO and Managing Director Collin Roche reflects on the private equity landscape, emphasizing the importance of value creation over merely capitalizing on rising prices. Roche highlights GTCR's multibillion-dollar exit from Worldpay as a prime example of their strategy: backing executive teams to implement operational and strategic changes that improve business performance and justify higher exit multiples. (Source: Bloomberg)...
07.05.26 - 19:36
Roche to buy digital pathology firm PathAI for up to $1.1B (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.26 - 19:00
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
 
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Trinke Tee, und du kommst zu Kräften. - Sprichwort China
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!